AXDX Stock Overview
An in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Accelerate Diagnostics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.58 |
| 52 Week High | US$2.09 |
| 52 Week Low | US$0.49 |
| Beta | 0.46 |
| 1 Month Change | -17.49% |
| 3 Month Change | -53.42% |
| 1 Year Change | -37.41% |
| 3 Year Change | -94.11% |
| 5 Year Change | -99.46% |
| Change since IPO | -63.90% |
Recent News & Updates
Recent updates
Market Participants Recognise Accelerate Diagnostics, Inc.'s (NASDAQ:AXDX) Revenues Pushing Shares 38% Higher
Apr 17
Accelerate Diagnostics spikes as Chief Technology Officer raises stake
Aug 30Need To Know: Analysts Are Much More Bullish On Accelerate Diagnostics, Inc. (NASDAQ:AXDX)
Aug 20Accelerate Diagnostics jumps 14% after beating Q2 estimates
Aug 15Need To Know: The Consensus Just Cut Its Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Estimates For 2022
Mar 15Accelerate Diagnostics And T2 Biosystems: Financial Woes Set To Continue In 2022
Jan 04Accelerate Diagnostics: An Investment Assessment
Sep 07Should You Take Comfort From Insider Transactions At Accelerate Diagnostics, Inc. (NASDAQ:AXDX)?
Feb 20
Accelerate Diagnostics foresees Q4 and FY2020 revenue below consensus
Jan 12Reflecting on Accelerate Diagnostics' (NASDAQ:AXDX) Share Price Returns Over The Last Three Years
Dec 29Shareholder Returns
| AXDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 9.0% | 5.4% | 7.0% |
| 1Y | -37.4% | 6.1% | 7.5% |
Return vs Industry: AXDX underperformed the US Medical Equipment industry which returned 6.1% over the past year.
Return vs Market: AXDX underperformed the US Market which returned 7.5% over the past year.
Price Volatility
| AXDX volatility | |
|---|---|
| AXDX Average Weekly Movement | 9.4% |
| Medical Equipment Industry Average Movement | 9.3% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: AXDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: AXDX's weekly volatility (9%) has been stable over the past year.
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1982 | 107 | Jack Phillips | acceleratediagnostics.com |
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States and internationally. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing (AST) of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides Accelerate PhenoTest BC Kit, a test kit for the system, which is indicated as an aid, in conjunction with other clinical and laboratory findings, in the diagnosis of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
Accelerate Diagnostics, Inc. Fundamentals Summary
| AXDX fundamental statistics | |
|---|---|
| Market cap | US$14.55m |
| Earnings (TTM) | -US$50.04m |
| Revenue (TTM) | US$11.70m |
1.2x
P/S Ratio-0.3x
P/E RatioIs AXDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AXDX income statement (TTM) | |
|---|---|
| Revenue | US$11.70m |
| Cost of Revenue | US$8.99m |
| Gross Profit | US$2.70m |
| Other Expenses | US$52.75m |
| Earnings | -US$50.04m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 23.12% |
| Net Profit Margin | -427.81% |
| Debt/Equity Ratio | -113.0% |
How did AXDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/28 10:32 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Accelerate Diagnostics, Inc. is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sean Lavin | BTIG |
| Garrett Nelson | CFRA Equity Research |
| Alexander Nowak | Craig-Hallum Capital Group LLC |